Skip to main content

Table 4 Number of patients with adverse event (AE) or serious adverse event (SAE) during survey

From: Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study

  Ramipril (n = 1,350) Diuretic (n = 661)
Type of adverse event n % n %
No AE 962 71.3 463 70.0
Any AE 388 28.7 198 30.0
   Serious AE 168 12.4 101 15.3
   Not serious 345 25.6 176 26.6
MedDRA ® primary System Organ Classes (SOC) V. 11.1 - (Serious) Adverse Events, n = 2011 (%) Ramipril Diuretic
  AE SAE AE SAE
Musculosceletal and connective tissue disorders 6.52 0.74 11.95 0.61
Infections and infestations 6.22 0.37 9.98 0.45
Metabolism and nutrition disorders 5.78 0.22 8.02 1.06
Respiratory, thoracic and mediastinal disorders 5.93 0.22 3.03 0.45
Nervous system disorders 3.41 1.70 6.66 3.78
Gastrointestinal disorders 3.48 1.04 4.24 1.36
Cardiac disorders 3.04 2.74 4.54 3.18
Vascular disorders 3.26 1.48 2.57 1.36
General disorders and administration site conditions 2.07 1.93 3.48 3.03
Injury, poisoning and procedural complications 2.22 1.04 3.18 1.36
Surgical and medical procedures 2.00 0.89 2.87 1.51
Neoplasms benign, malignant and unspecified (incl cysts and polyps) 1.93 2.22 2.12 2.12